European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Cite this article
Potential therapeutic vaccine strategies and relevance of the immune system in uterine cervical cancer
1 Research Institute of Oncology (IPON), Discipline of Immunology, Discipline of Gynecology and Obstetrics, University of Triângulo Mineiro, Uberaba, MG (Brazil)
Eur. J. Gynaecol. Oncol. 2008, 29(1), 10–18;
Published: 10 February 2008
The interaction of HPV with the immune system has been studied, but the results are still inconclusive for several reasons. Until now, we have not been able to understand the mechanisms of immune system regulation in the uterine cervix. HPV infection does not unleash an inflammatory response, and consequently an efficient and specific immune response against the virus. Moreover, an understanding of HPV infection and local immune response is indispensable for the development of new bioactive drugs and therapies for patients with both non invasive and invasive tumors, mainly for patients that do not present regression with radiotherapy or chemotherapy or in whom the tumors are surgically unresectable. The aim of this review is to provide support in understanding potential mechanisms used by the immune system to destroy neoplastic cells, comparing the immunotherapy used in cancer and discussing the possibility of developing new drugs based on these mechanisms of action.
Uterine cervical cancer